(2S)-5-(carbamoylamino)-2-[2-[(4-isothiocyanatophenyl)methyl]hydrazinyl]pentanoic acid;(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-5-(carbamoylamino)-2-[2-[(4-isothiocyanatophenyl)methyl]hydrazinyl]pentanoic acid;(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• 化学式: C24H38N6O7S
• 分子量: 554.7
• InChiKey: IJDHKQBQCHYKEL-QIUDTCLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.54
• 重原子数：
  38
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  237
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• Biologically active molecules, conjugates thereof, and therapeutic uses
  申请人：REGENERON PHARMACEUTICALS, INC.

  公开号：US10570151B2

  公开（公告）日：2020-02-25

  The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

  本公开涉及用于将生物活性分子与配体共价连接的连接体化合物。所公开的化合物还涉及生物活性分子和配体共轭物，其中生物活性分子通过连接体与配体连接。本公开进一步提供了包含生物活性分子-配体共轭物的组合物、改变异常细胞生长的方法以及使用共轭物或组合物进行治疗的方法。
• BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：EP2968593A1

  公开（公告）日：2016-01-20
• [EN] BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES<br/>[FR] MOLÉCULES BIOLOGIQUEMENT ACTIVES, LEURS CONJUGUÉS, ET UTILISATIONS THÉRAPEUTIQUES
  申请人：REGENERON PHARMA

  公开号：WO2014145090A1

  公开（公告）日：2014-09-18

  The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule -ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.